Biovision
BioSim™ HER2 mab (Human) ELISA Kit
- SKU:
- 26-E4376
- Availability:
- Usually Shipped in 5 Working Days
- Size:
- 100 Assays
- Storage Conditions:
- 4°C
- Shipping Conditions:
- Gel Pack
- Shelf life:
- 12 months
Description
Trastuzumab (Herclon®, Herceptin®) is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Trastuzumab has antitumor activity against HER2-positive human breast tumor cells in laboratory models and is active for the trea™ent of women with HER2-overexpressing breast cancers. This antibody was approved in 1998 for clinical use for HER2 overexpressing metastatic breast cancer. In HER2 overexpressing cells, trastuzumab markedly down-regulates HER2 expression by accelerating receptor endocytosis and degradation and inhibits cell cycle progression by inducing the formation of p27Kip1/Cdk2 complexes. BioSim™ Trastuzumab ELISA kit has been developed for specific quantification of Trastuzumab concentration in human serum or plasma with high sensitivity and reproducibility.
Alternate Name: N/A
Tag Line: A Sandwich ELISA kit for the quantitative measurement of Trastuzumab in human serum or plasma.
Summary: • Detection method- Absorbance (450 nm) • Species reactivity- Human • Application- quantitative measurement of Trastuzumab in human serum and plasma
Detection Method: Absorbance (450 nm)
Sample Type: Human serum and plasma
Species Reactivity: Human
Applications: This ELISA kit is used for quantitative measurement of Trastuzumab in human serum and plasma
Features & Benefits: • Easy, convenient, sensitive and time-saving method to measure the level of Trastuzumab in human serum and plasma. • Detection Range: 11 - 300 ng/ml • Sensitivity: Quantitative limit: 11 ng/ml, Detection limit: 2 ng/ml • Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) • Recovery rate: 85 – 115% with normal human serum samples with known concentrations • Cross Reactivity: No significant cross-reactivity or interference with other proteins present in native human serum or other therapeutic immunoglobulins.